www.cbsnews.com/news/melanom...
“Before immunoncology, we weren't really able to say the word 'cure' for these patients who were suffering from Stage IV metastatic disease, and now we can," Zhou said. "It's really, truly transformational for these patients."
“Before immunoncology, we weren't really able to say the word 'cure' for these patients who were suffering from Stage IV metastatic disease, and now we can," Zhou said. "It's really, truly transformational for these patients."
https://www.cbsnews.com/news/melanoma-metastatic-stage-iv-cancer-brain-tumor-pregnancy/"Before
July 13, 2026 at 4:32 AM
www.cbsnews.com/news/melanom...
“Before immunoncology, we weren't really able to say the word 'cure' for these patients who were suffering from Stage IV metastatic disease, and now we can," Zhou said. "It's really, truly transformational for these patients."
“Before immunoncology, we weren't really able to say the word 'cure' for these patients who were suffering from Stage IV metastatic disease, and now we can," Zhou said. "It's really, truly transformational for these patients."
Terrific #ImmunoEngineering #AdoptiveTcellTherapy #Tcells Update from @vicalbarran.bsky.social et al at @nature.com communications | OPEN ACCESS | Online Now | #CARTcells | #TILs | #TCR | #immunotherapy | #immunoncology |
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Unlocking the potential of engineered immune cell therapy for solid tumors - Nature Communications
Adoptive cell therapy has emerged as a promising approach for treating advanced solid malignancies. Genetic engineering techniques represent an exciting area of research for the development of cellula...
www.nature.com
January 30, 2025 at 3:59 PM
Terrific #ImmunoEngineering #AdoptiveTcellTherapy #Tcells Update from @vicalbarran.bsky.social et al at @nature.com communications | OPEN ACCESS | Online Now | #CARTcells | #TILs | #TCR | #immunotherapy | #immunoncology |
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab.
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...
ClinicalTrials.gov
clinicaltrials.gov
September 4, 2024 at 11:57 AM
Xencor has terminated developed of IL-12-Fc, a reduced potency cytokine fusion protein. #XmAb662 had been in a solid tumor basket study with #pembrolizumab.
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...
$XNCR #biosky #biotech #immunoncology
clinicaltrials.gov/study/NCT059...
A taste of some of the research we heard about during Day 1. #CancerResearch #microbiome #immunoncology #biologicaltherapies
January 29, 2024 at 7:58 PM
A taste of some of the research we heard about during Day 1. #CancerResearch #microbiome #immunoncology #biologicaltherapies
Cross-Priming in #Cancer #Immunology & #Immunotherapy | Definitive Treatise Now Breaking at @nature.com Reviews Cancer |
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Cross-priming in cancer immunology and immunotherapy - Nature Reviews Cancer
In this Review, Luri-Rey et al. present evidence for the crucial role of conventional type 1 dendritic cells in cross-presenting antigens from other cells via the major histocompatibility complex clas...
www.nature.com
January 30, 2025 at 12:20 PM
Dr. Gilberto Lopes Joins Immorta Bio: A Leap into Longevity and Cancer Treatment#USA#Miami#Immorta_Bio#SenoVax#Gilberto_Lopes
Dr. Gilberto Lopes Joins Immorta Bio: A Leap into Longevity and Cancer Treatment
Renowned lung cancer expert Dr. Gilberto Lopes has joined Immorta Bio's Strategic Advisory Board to advance longevity therapies and immunoncology.
third-news.com
September 17, 2025 at 2:24 PM
Dr. Gilberto Lopes Joins Immorta Bio: A Leap into Longevity and Cancer Treatment#USA#Miami#Immorta_Bio#SenoVax#Gilberto_Lopes
a few of my #immunoncology and #celltherapy talks
studio.youtube.com/channel/UCXI...
plus bonus features "The dog and I..." series
studio.youtube.com/channel/UCXI...
plus bonus features "The dog and I..." series
YouTube
Share your videos with friends, family, and the world.
studio.youtube.com
November 11, 2024 at 8:52 PM
a few of my #immunoncology and #celltherapy talks
studio.youtube.com/channel/UCXI...
plus bonus features "The dog and I..." series
studio.youtube.com/channel/UCXI...
plus bonus features "The dog and I..." series
Early days, indeed. I'm excited by immunoncology, but part of the problem is that cancers are cancers because they evade or counter immune responses. Still, there's always hope.
December 7, 2024 at 1:21 AM
Early days, indeed. I'm excited by immunoncology, but part of the problem is that cancers are cancers because they evade or counter immune responses. Still, there's always hope.